Trial Profile
A Single-Arm Open-Label Multi-Centre Extension Study of Pertuzumab Administered As a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Trastuzumab; Vinorelbine
- Indications Breast cancer; HER2 positive breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Chugai Pharmaceutical; Roche
- 19 Apr 2023 Planned End Date changed from 31 May 2024 to 31 Dec 2025.
- 19 Apr 2023 Planned primary completion date changed from 31 May 2024 to 31 Dec 2025.
- 27 Oct 2022 This trial has been completed in Poland according to European Clinical Trials Database record.